Bimatoprost is a prostaglandin F2-α agent which is currently FDA indicated for the treatment of elevated intraocular pressure and hypotrichosis of the eyelashes. The success of bimatoprost in treating hypotrichosis of the eyelashes, which is when there is an inadequate amount of eyelashes, has led to investigating its use in other types of hair loss.
Androgenetic alopecia (AGA), also known as male pattern baldness, is the most common cause of hair loss in men, affecting about 80% of Caucasian males. It is characterized by hair follicles that gradually decrease in size, leading to baldness over time. AGA is usually the result of a genetic predisposition; however, evidence shows that the cause may also be androgen-related. Dihydrotestosterone (DHT) is the primary androgen involved in AGA and men affected by this condition will have increased serum concentrations of DHT.